In addition to the T2-FLAIR mismatch, the hypermethylation of the O-(6)-methylguanine-DNA-methyltransferase (MGMT) promoter is a known prognostic biomarker for astrocytomas. Here, MGMT is linked to astrocytoma (excluding glioblastoma).